{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:47:53Z","timestamp":1781736473982,"version":"3.54.5"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg\/kg of body weight\/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.<\/jats:p>","DOI":"10.1128\/aac.00361-09","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T20:45:41Z","timestamp":1242074741000},"page":"3122-3125","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis"],"prefix":"10.1128","volume":"53","author":[{"given":"Brad","family":"Spellberg","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California"},{"name":"the David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Medical Microbiology and Immunology, University of Wisconsin School of Medicine, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Perez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Southern California (USC) School of Medicine Department of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Anglim","sequence":"additional","affiliation":[{"name":"Long Beach Public Department of Health, Long Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Bonilla","sequence":"additional","affiliation":[{"name":"Summa Health System, Akron, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E.","family":"Mathisen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Olive View-UCLA Medical Center, Sylmar, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California"},{"name":"the David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.1.231"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116419"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.beha.2004.09.002","volume":"18","year":"2005","unstructured":"Cappellini, M. D. 2005. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract. Res. Clin. Haematol.18:289-298.","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycres.2007.03.004"},{"key":"e_1_3_2_7_2","unstructured":"Important information about Exjade (deferasirox) tablets for oral suspension 2007"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl350"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32338"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01065-06"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01611-07"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.3.556-569.2005"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","volume":"83","year":"2008","unstructured":"Vichinsky, E. 2008. Clinical application of deferasirox: practical patient management. Am. J. Hematol.83:398-402.","journal-title":"Am. J. Hematol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00361-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00361-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:08:46Z","timestamp":1645456126000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00361-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1128\/AAC.00361-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.00361-09","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4015968.3779075","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"2009-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-05-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}